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Volume And StruCture of AntihyPertenSiVe drugS ConSumPtion in 
ukrAine
Iakovlieva L., Mishchenko O., Bezditko N., Gerasymova O., Kyrychenko O., Tkachova O., 
Matyashova N.
National University of Pharmacy, Kharkiv, Ukraine
Objectives: Arterial hypertension (AH) largely determines the high mortality rate 
and disability of working age persons from coronary heart diseases. In Ukraine 
in 2012 according to official statistics 12.1 million patients with AH were regis-
tered. It is 32.2% of the adult population. The purpose of the study - assessment 
structure and volume of antihypertensive drugs (AHDs) consumption during 2008-
2013 in Ukraine. MethOds: Analysis of AHDs consumption was performed using 
ATC/DDD-methodology and data of drugs supply in informational-search system 
“Pharmaceuticals” of company MORION during 2008-2013. Consumption of AHDs 
was determined in the indicator: DDDs / 1000 inhabitans / day (DIDs). AHDs of the 
first-line: thiazide and thiazide-type diuretics, β -blockers, calcium channel block-
ers, ACE inhibitors, angiotensin II receptor blockers and the second line: α -block-
ers, central antiadrenergic drugs, peripheral vasodilators were analyzed. Results: 
Volume of AHDs consumption increased from 60,64 DIDs in 2008 to 96,43 DIDs in 
2013. About 6.08% - 9.6% of inhabitans take one DDD per day. Recalculation vol-
umes of AHDs consumption for a total aggregate of patients with AH showed that 
only 23% - 36% of patients receive treatment. This testifies to the low adherence of 
patients to treatment. A comparison the volumes of AHDs consumption has shown 
that the consumption of AHDs in Ukraine is less, but stroke mortality is higher than 
in the developed countries. Consumption of AHDs of the first line accounts for a 
large share which increased from 83.7% in 2008 to 89.3% in 2013. Consumption of 
AHDs of the second line decreased. cOnclusiOns: Structure of AHDs consump-
tion in Ukraine indicates compliance of antihypertensive therapy to current clinical 
guidelines. The consumption of AHDs in Ukraine is less than in other countries, 
so the most urgent problem for Ukraine is to find mechanisms for increasing the 
adherence of patients to hypertension treatment.
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outComeS, heAlth CoStS And uSe of StAtinS in 6,226 PAtientS 
Admitted in 2011 for An ACute CoronAry Syndrome (ACS) oCCurring 
in A lArge Community Setting of 2,989,512 SubjeCtS
Maggioni A.P.1, Cinconze E.2, Rossi E.2, De Rosa M.2, Esposito I.3, Martini N.3
1ANMCO Research Center, Florence, Italy, 2CINECA Interuniversity Consortium, Casalecchio di 
Reno, Italy, 3Accademia Nazionale di Medicina, Roma, Italy
Objectives: To assess in a community setting how patients discharged alive after 
an ACS are treated with statins. Specifically, the rate of prescription, the dosages and 
1-year adherence have been evaluated. MethOds: From the ARNO Observatory, we 
carried out a record linkage analysis of discharge records for ACS and prescription 
databases, which included 2,989,512 subjects of 7 Local Health Authorities from 
Northern to Southern Italy. The accrual period lasted from January 1 to December 
31, 2011. Results: Of the 2,989,512 subjects, 6,226 (2.1‰) were hospitalized for ACS 
over the 12 months of observation, 58% of patients were aged more than 70 years, 
females accounted for 36% of the cases, diabetes was reported in 31%. In-hospital 
all-cause death was 4.6%. Of the patients discharged alive, 69.9% received a statin 
treatment at the time of discharge. High dosage of statins were used in 70.4% of 
cases. After 1 year follow-up, adherence to treatment was observed in 71.7% of 
patients. Over the 1-year follow-up, 63.3% of the patients needed to be readmit-
ted again (50.4% for cardiovascular causes). The average yearly cost per patient for 
the total ACS population was 16,897€ /year (drugs, 1,692€ ; hospitalizations, 14,198€ ; 
diagnostic and outpatient visits, 1,007€ ). cOnclusiOns: In a community setting, 
the rate of prescription of statins after an ACS seems to be at least suboptimal. 
However, the dosages of prescribed statins suggest that the use of intensive statin 
treatment increased over the last few years. Prescription continuity over time was 
not adequately followed. Patients with ACS have high direct healthcare costs, rehos-
pitalization being the main cost driver. There is still a gap between evidence based 
recommendations and what actually happens in the routine clinical practice, surely 
determining a high social and economical burden for the national health structures.
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PhySiCiAn’S AdherenCe to treAtment guidelineS in deeP Vein 
thromboSiS At An indiAn tertiAry heAlthCAre fACility
Tiwari P.1, Sunarikani R.1, Malhotra S.2
1NIPER MOHALI INDIA, MOHALI, India, 2Private Hospital, MOHALI, India
Objectives: Despite the availability of effective prophylactic and therapeutic 
options, VTE continues to be under diagnosed and undertreated. The incidence of 
DVT in India, however, is comparable to that in the Western countries. This study 
aimed to assess the adherence of treatment guidelines in the prophylaxis of DVT 
and evaluated the risk factors associated with DVT. MethOds: The prospective 
study was carried out at an Indian tertiary healthcare setting where the patients 
were enrolled in the study as per the defined inclusion and exclusion criteria. The 
results are based on findings from a total of 230 patients. The patients were clas-
sified into four different categories based on the risk of DVT- low, moderate, high 
and highest. Results: The results are based on data obtained from 158 female 
and 72 male patients. The average age of the patients was found to be 62.1±0.9 
yrs. The average age of female patients was found to be statistically significantly 
higher than the average age of male patients. Of 230 patients, 207 patients received 
Enoxaparin/ Rivaroxaban/ Diateparin for prophylaxis and 5 patients through DVT 
pump and limb physiotherapy. It was found that 18 patients did not receive any type 
of DVT prophylaxis; and, out of 18 patients, 10 were managed for DVT prophylaxis 
with active toe movements. The adherence to the pharmacological prophylaxis 
was found to be 92.2%. cOnclusiOns: The results of this study have shown that 
the adherence to ACCP guidelines in DVT prophylaxis in this study population was 
high (92.2%). Further, an association between surgery (major surgery, orthopaedical 
surgery), age and DVT risk appears to be existent.
Objectives: Clinical trials comparing rivaroxaban or dabigatran to warfarin 
show similar results for major and non-major clinically relevant bleeding. Post-
marketing data regarding bleeding rates for these new oral anticoagulants (NOACs) 
is lacking. Our goal was to evaluate bleeding related outcomes with NOACs using 
a disproportionality analysis of spontaneous adverse event reports. MethOds: 
We evaluated the FAERS database from 10/2011 – 12/2012 to compare frequency 
of events in reports of rivaroxaban, dabigatran, and warfarin related to fatal and 
non-fatal bleeding. Reports were included if the anticoagulant was the primary 
suspected agent for the event. Reporting odds ratio (ROR) and proportional report-
ing ratio (PRR) were calculated to estimate risk for each anticoagulant. Results: 
Of 22,244 eligible adverse drug reports for the anticoagulants, 7661 (34%) bleed-
ing reports were submitted, with 1868 (24%) deaths, 5028 (66%) hospitalizations 
and 1040 (14%) life-threatening events. Dabigatran was the most commonly 
reported anticoagulant exposure among bleeding cases (n= 5203, 68%). Of the 
bleeding cases associated with dabigatran, death was reported in 29%, hospi-
talization in 67%, and life-threatening events in 15% of cases. The odds of expo-
sure for fatal bleeding was significantly higher with dabigatran (ROR 2.28, 95% 
confidence interval [CI] 2.02-2.56) and significantly lower with rivaroxaban (ROR 
0.75, CI = 0.69-0.8) and warfarin (ROR 0.53, CI = 0.44-0.63). PRR indicated sig-
nificantly increased risk of non-fatal bleeding with dabigatran (PRR = 2.12, CI 
= 1.99-2.24) and warfarin (PRR = 1.27, CI = 1.17-1.38) with a significant decrease 
associated with rivaroxaban (PRR 0.8, CI = 0.75-0.86). cOnclusiOns: Among the 
NOACs, patients having fatal and non-fatal bleeding were found to have higher 
odds of dabigatran exposure and significantly lower odds of rivaroxaban expo-
sure. Though FAERS is subject to significant bias, the results suggest dabigatran-
related bleeding is higher in clinical practice and rivaroxaban may be a safer 
alternative.
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AntihyPertenSiVe drug utilizAtion in elderly outPAtientS in SerbiA
Tomas A., Horvat O., Paut Kusturica M., Tomic Z., Ban M., Sabo A.
Faculty of Medicine, Novi Sad, Serbia and Montenegro
Objectives: Arterial hypertension represents a major cause of morbidity and 
mortality among elderly population in Novi Sad, Serbia. The aim of this study 
was to analyze patterns and address financial aspects of antihypertensive drug 
utilization among elderly outpatients (> 60). MethOds: Data on antihypertensive 
issued on prescription were collected from all state-owned pharmacies in Novi Sad 
(population 350,000) from September 2011 to February 2012. Consumption was cal-
culated using the ATC/DDD methodology, and results were expressed in DDD/1000 
inhabitants/day. DU90% (drug utilization 90%) segment and price per DDD were 
determined. Results: The total use of antihypertensives among population > 60 
years in Novi Sad, Serbia was 203.1 DDD/1000inh/day. ACE inhibitors were the most 
frequently used drugs and accounted for 58.44% of total consumption, followed 
by calcium channel blockers (23.51%) and beta-blockers (11.10%). Consumption of 
diuretics (4.29%) and angiotensin receptor antagonists (< 3%) was low. High use of 
ACE inhibitors was also reflected in DU90% profile. Even though most commonly 
prescribed drug was amlodipine (18.49%), out of 16 drugs within DU90% segment, 
10 were ACE inhibitors or ACE inhibitors/diuretics fixed combinations. Average 
price per DDD within DU90% was 0.09 euro per DDD whereas it was 0.12 euro 
per DDD for drugs beyond the DU90% segment. cOnclusiOns: High consump-
tion of ACE inhibitors and disregard to other antihypertensive agents points to 
therapeutic irrationalities which can have considerable clinical and economic 
consequences. Targeted education may both improve efficacy of treatment of 
hypertension in elderly and provide significant savings. Acknowledgement: This 
work was supported by the Ministry of Science and Technological Development, 
Republic of Serbia, project No. 41012.
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uSe of SeleCtiVe-Serotonin reuPtAke inhibitorS And PlAtelet 
AggregAtion inhibitorS Among indiViduAlS With Co-oCCurring 
heArt diSeASe And dePreSSion or Anxiety
Thornton J.D., Agarwal P., Sambamoorthi U.
West Virginia University, Morgantown, WV, USA
Objectives: Anxiety and depression are prevalent in individuals with coronary 
heart disease. Selective-serotonin reuptake inhibitors (SSRI) are first-line therapy 
for many anxiety and depression disorders. Platelet aggregation inhibitors (PAI) 
are the cornerstone of therapy for various types of heart disease. These medi-
cations are relatively contraindicated due to an increased risk for many types 
of bleeding. The purpose of the study was to examine the prevalence and pre-
dictors of use of both SSRI and PAI among individuals with co-occurring heart 
disease and anxiety or depression. MethOds: Respondents who were age 22 
years and older, alive throughout the study period, diagnosed with heart dis-
ease and co-occurring anxiety or depression (n= 1,253) in 2009-11 of the Medical 
Expenditures Panel Survey were included. Use of treatment was grouped as: 1) 
SSRI and PAI, 2) SSRI or PAI, and 3) Neither SSRI or PAI. Results: Overall, 11.2% 
used both SSRI and PAI, 46.3% used SSRI or PAI, and 42.5% used neither SSRI 
nor PAI. Significant subgroup differences were observed in the use of treat-
ment. Females were less likely to be prescribed the inappropriate combination 
[AOR 0.57 (95%CI= 0.36-0.92)] while respondents having education less than 
high school [AOR 2.27 (95%CI= 1.30-3.99)] or a diagnosis of diabetes [AOR 2.13 
(95%CI= 1.28-3.53)] were more likely to be prescribed the inappropriate combina-
tion. cOnclusiOns: In this sample potentially inappropriate medication use 
was prevalent. Patients with less education or lower socioeconomic status are 
more likely to have health disparities and are at higher risk for both physical and 
mental health conditions. In this study, the patients with lower levels of education 
were more likely to be receiving an inappropriate combination of medications. 
The strong association with diabetes diagnosis and treatment choice is important 
because of the increased risk for bleeding in patients who received treatment for 
diabetes.
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female; 48% control patients. Overall, 15.8% of patients experienced hyperkalemia: 
9.8% had ≥ 1 mild hyperkalemia event and 6.1% had moderate/severe events. 8.5% of 
control patients experienced hyperkalemia events compared with 23.5% of patients 
with HF, 29.5% of patients with CKD stages 3-4, and 47.6% of patients with HF and 
CKD stages 3-4. Hyperkalemia was more prevalent in patients with each measured 
comorbidity compared to control patients, and its severity increased with CKD sever-
ity (all comparisons, P< 0.0001). Moderate/severe hyperkalemia was more prevalent in 
patients with later-stage CKD compared to patients with earlier stage kidney disease. 
Prevalence of hyperkalemia was generally higher in patients aged ≥ 65 years than in 
similarly comorbid patients aged < 65 years. cOnclusiOns: A retrospective analysis 
of electronic medical record data demonstrated that hyperkalemia was more common 
in patients with HF and/or CKD —especially in those with more advanced disease—
than in patients without these comorbidities.
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VenouS thromboemboliSm PreVAlenCe in frenCh And uS hoSPitAlS: 
ComPAriSon on the bASiS of the nAtionAl dAtA bASeS
Allaert F.1, Quantin C.2, Benzenine M.2
1Medical evaluation Chair ESC Dijon, Dijon, France, 2university hospital Dijon, Dijon, France
Objectives: describe the national prevalence of deep vein thrombosis (DVT) and 
pulmonary embolism (PE), among patients hospitalized in private and public French 
hospitals and to compare it to those described in US Hospitals. MethOds: The 
statistics are from the national PMSI MCO databases inspired by the US Medicare 
system. Data are encoded using ICD10. The codes used for VTE are I801 to I809 
for DVT and codes I260, I269 for PE. The analyses identify all VTE, DVT without PE 
(DVT) and PE with or without previous/associated DVT. The study data cover the 
period 2005 to 2011. The French data are compared to those issued in the Morbidity, 
Mortality Weekly Report of the Centre for Disease Control and Prevention. Results: 
Data from the national database reveal that over the period 2005 to 2011 the inci-
dence of hospital stays came to 860 343 (1.09%) for VTE, with 428 261 (0.543%) for 
DVT without PE and 432 082 (0.548%) for PE. The mean number of VTE hospitalized 
per year over the period was 122 906, including 61 180 for DVT and 61 726 for PE. 
Out of the French population > 18y, those 122 906 VTE correspond to an incidence of 
247 hospitalizations for 100 000 vs. 239 in the USA for the VTE, of 124 vs. 118 for the 
DVT without EP and of 123 vs. 121 for the EP which is very similar. These instances 
of VTE occurred in France for 43.4% in men vs. 45.8% in the USA and 56.6% vs. 
54.2% in women. cOnclusiOns: French VTE incidence is high and similar to those 
described in the USA. These results point out an alarming situation that questions 
the quality of prevention and/or its effectiveness. VTE prevention policies must 
be strengthened in hospitals for the sake of patients and healthcare savings alike.
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the PreVAlenCe And oddS-rAtioS of Self-rePorted diAgnoSiS 
of hyPertenSion Among uS AdultS by rACiAl/ethniC SubgrouPS, 
exAmining the joint effeCt of multiPle riSk fACtorS: nAtionAl 
heAlth interVieW SurVey, 2004 - 2013
Godwin O., Brown L.M.
Chapman University, Irvine, CA, USA
Objectives: The differences in prevalence and odds ratios of self-reported hyper-
tension among racial/ethnic groups in the United States have not been fully 
explained. This current study focused on investigating the prevalence and the joint 
effect of multiple risk factors on self-reported hypertension in the United States 
ethnic subgroups. MethOds: A cross-sectional study design was used to determine 
the prevalence of self-reported hypertension among non-Hispanic whites, non-
Hispanic blacks, and Hispanics in the National Health Interview Survey (NHIS), 2004 
– 2013. An estimated total of 607 million cases of self-reported hypertension among 
United States adults 18 years or older was identified. Logistic regression models 
were utilized to estimate the odds ratios (OR) and 95% confidence intervals for the 
selected risk factors associated with hypertension. Results: The overall prevalence 
of self-reported hypertension in the non-Hispanic whites, non-Hispanic blacks, and 
Hispanics was 29.4%, 35.4%, and 19.5% respectively. After adjusting for the selected 
risk factors , a subgroup analysis of subjects aged 18-44 years non-Hispanic black 
males and females were found to have statistically significant lower odds of self-
reporting hypertension compared to non-Hispanic whites (adjusted odds ratios 
(AOR), 0.62; 95% CI, 0.57-0.66; P < 0.01 males; AOR, 0.62; 95% CI, 0.58-0.66; P < 0.01 
females, respectively). In contrast, non-Hispanic blacks aged 45 to 64 years (AOR, 
1.42; 95% CI, 1.33-1.53; P < 0.01 males; AOR, 2.39; 95% CI, 2.24-2.54; P < 0.01 females, 
respectively) had statistically significant higher odds of self-reporting hypertension 
compared to non-Hispanic whites aged 45 to 64 years. cOnclusiOns: This result 
challenges the commonly held belief that all blacks have a higher prevalence of 
hypertension, and underscores the need for data segmentation to further deter-
mine with more precision the age at which non-Hispanic blacks shift from being 
less likely to self-reporting hypertension to more likely than non-Hispanic whites.
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geogrAPhiC differenCeS in AVAilAbility of AntihyPertenSiVe 
mediCAtionS: A ComPAriSon of AuStrAliA, CAnAdA, SAudi ArAbiA, uk, 
And the uS
Almutairi H.1, Alzarea A.I.1, Seoane-Vazquez E.1, Mekary R.2
1MCPHS University, Boston, MA, USA, 2MCPHS University, N/A, MA, USA
Objectives: To compare the number of antihypertensive medications that were 
approved by the US Food and Drug Administration, the UK Medicines and Healthcare 
Products Regulatory Agency, the Australian Therapeutic Goods Administration, 
Health Canada, and the Saudi Food & Drug Authority as of [2014]. MethOds: 
Antihypertensive medications information was collected from the websites of the 
agencies. Hypertension prevalence by country was collected from the WHO website. 
Descriptive analysis was conducted in the study. Spearman correlation was used 
to estimate the correlation between the number of approvals and hypertension 
prevalence. SAS version 9.3 was used in the analysis. Results: The prevalence 
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trendS in AntihyPertenSiVe mediCAtion uSe in uS offiCe-bASed 
PrACtiCeS: Are elderly PAtientS treAted diffrerently?
Gu A.1, Yue Y.2, Argulian E.3
1St. John’s University, Jamaica, NY, USA, 2Baruch College/CUNY, New York, NY, USA, 3Mount Sinai 
St. Luke’s Hospital, New York, NY, USA
Objectives: 1) To investigate recent trends in antihypertensive medication pre-
scribing among US adults with hypertension in office-based practices; 2) To deter-
mine if there are differences in the classes of antihypertensive agents prescribed for 
the elderly population as compared with younger patients. MethOds: The latest 
available National Ambulatory Medical Care Survey (NAMCS) (2003 – 2010) were ana-
lyzed. All encounters with ICD-9 codes for essential hypertension (eg, 401.0, 401.1, 
or 401.9) and patients aged ≥ 18 years were identified. Multivariate logistic regres-
sion analyses determined the adjusted associations between age (< 60 years, ≥ 60 
years) and the prescription use of antihypertensive classes, as well as prescribing 
year trend. Variance estimates were computed with the Taylor series linearization 
approximation. Results: Approximately 674 million weighted office visits were 
included in the analysis. Overall, the prescription of antihypertensive medication 
increased from 69.2% in 2003 to 2004 to 78.8% in 2009 to 2010 (P trend< 0.01) and 
the upward trend was consistent in both age groups. This was accompanied by an 
improvement in the overall hypertension control (from 39.6% to 49.3%, P trend< 0.01). 
The proportions of visits with β -blocker (from 25.4% to 34.7%, P trend< 0.01) and 
angiotensin receptor blocker (ARB) prescriptions (from 17.0% to 22.1%, P trend= 0.02) 
increased for older patients. Prescribing rates for diuretics, β -blockers, and calcium-
channel blockers (CCBs) were significantly higher among patients aged ≥ 60 years 
compared to their younger counterparts, while rates for ARBs and angiotensin-
converting enzymes (ACEIs) were relatively comparable between the two groups. 
The increase in use of β -blockers in older patients persisted after excluding patients 
with congestive heart failure and ischemic heart disease. cOnclusiOns: In office-
based practices, antihypertensive medication prescribing among US adults with 
hypertension increased significantly in recent years which was accompanied by 
some improvement in hypertension control. The prescribing patterns differed 
among younger and older patients but continuous use of β -blockers without other 
compelling indications raises concerns.
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ComPAriSon of different metAboliC Syndrome CriteriA And 
indiViduAl riSk fACtorS in the riSk PrediCtion of CArdioVASCulAr 
And ChroniC diSeASeS
Bhounsule P., Peterson A.M.
University of the Sciences in Philadelphia, Philadelphia, PA, USA
Objectives: (1) To compare risks posed by the metabolic syndrome (MetS) diagnosed 
with four different criteria and cardiovascular risk factors in the development of 
diabetes mellitus 2 (T2D), cardiovascular disorders and other chronic disorders. (2) To 
determine if modification should be made to existing MetS definitions and standards 
of diagnosis of high risk patients. MethOds: A combination of NHANES 2009-2010 
and 2010-2011 databases formed our study cohort. MetS criteria included harmo-
nized 2009 World Health Organization definition, criteria from National Cholesterol 
Education Program Adult Treatment Panel III (NCEP-ATP III), International Diabetes 
Federation (IDF) and European Group for Study of Insulin Resistance (EGIR). Individual 
cardiovascular risk factors included smoking, alcoholism, albuminurea, elevated 
C-reactive protein levels and heredity of diabetes and cardiovascular disorders. Risk 
prediction was carried out for chronic disorders such as diabetes, cardiovascular dis-
orders, arthritis, asthma, emphysema, bronchitis, cancer and AIDs. Adjusted relative 
risk (RRs) using Poisson regression was calculated for each criteria and individual risk 
factors. Results: MetS failed to predict risk for cardiovascular disorders. However 
albuminurea (RR= 2.25), smoking (RR= 2.16) and heredity (RR= 1.52) posed a risk for 
cardiovascular disorders. All except smoking (0.32) demonstrated high risk for asthma. 
Smoking (RR= 4.15) along with all the MetS criteria (RR with WHO= 2.63; NCEP= 3.16; 
IDF= 5.67) except European criteria (RR= 0.67) predicted risk for emphysema. MetS 
(RR with WHO= 2.24; Europe= 5.43; NCEP= 3.31; IDF= 2.66) and albuminurea (RR= 1.49) 
were good predictors of kidney conditions. Similarly MetS (RR with WHO= 3.67; 
Europe= 6.33; NCEP= 4.24; IDF= 1.89), albuminurea (RR= 2.94), alcoholism (RR= 3.08) and 
heredity (RR= 3.74) were associated with risk for liver conditions. No MetS criteria and 
individual risk factors showed an association with risk for AIDS. cOnclusiOns: 
Overall European MetS criteria emerged as the strongest risk predictor for chronic 
conditions. The RRs of individual risk factors depict significant chronic disease pre-
dicting ability. Recommendations may be made to policy makers to alter or make 
additions to the current MetS definition.
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hyPerkAlemiA iS highly PreVAlent in PAtientS With CArdiorenAl 
ComorbiditieS ComPAred to PAtientS Without theSe ComorbiditieS
Latts L.M.1, Reaven N.L.2, Funk S.E.2, McGaughey K.J.3, Adamson R.T.4
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Objectives: To investigate the prevalence of hyperkalemia in patients with chronic 
kidney disease (CKD) or heart failure (HF). MethOds: De-identified medical records 
(2007-2012) from a US population aged ≥ 5 years with ≥ 2 potassium (K+) readings were 
evaluated. Inclusion criteria: ≥ 1 K+ value between 2.5 and 10 mEq/L during 2008 to 
2012. Exclusion criteria: acute kidney injury (AKI). Hyperkalemia was classified as mild 
(K+ 5.1 to 5.4 mEq/L) or moderate/severe (K+ ≥ 5.5 mEq/L) based on patient’s highest 
measured value. Patient comorbidities were assessed: CKD by stage, end-stage renal 
disease (ESRD), HF, diabetes, and disease combinations. Control patients had no CKD 
stage 2+, ESRD, HF, diabetes or AKI. Chi-square tests assessed whether prevalence of 
hyperkalemia differed significantly between control patients and those with comor-
bidities. Hyperkalemia prevalence was also compared by age group (< 65 years vs 
≥ 65 years). Results: 1,636,337 patients were evaluated; mean age, 56 years; 56% 
